RA3 + RACM7

RA3 + RACM7 appears to be a combination therapy for rheumatoid arthritis (RA). While the specific identities of "RA3" and "RACM7" are not established in standard pharmaceutical references or clinical trial registries as of June 2025, the naming convention suggests these may be investigational code names for drugs or drug regimens used in combination. Combination therapies are common in RA treatment and often involve disease-modifying antirheumatic drugs (DMARDs), biologics, or other agents to improve efficacy and reduce disease progression. The mechanism of action would depend on the specific agents involved; typical mechanisms include immunosuppression, cytokine inhibition, or modulation of immune cell activity[1].